November 2, 2012
ImmuVen Receives $297,000 Phase I Award from NIH
- ImmuVen was recently awarded a Phase I SBIR totaling more than $297,000 from the National Institute of Allergy and Infectious Disease (NIAID). This grant will further the development of ImmuVen’s proprietary soluble, high-affinity T cell receptor technology for use in detection of toxins from Staphylococcal aureus in clinical samples as well as in the food supply. This new award comes on the heals of a Phase II SBIR from NIAID to continue ImmuVen’s work on soluble, high-affinity T cell receptors as a therapeutic for neutralizing S. aureus toxins involved in various diseases. “The awarding of NIH grants not only enables our continued scientific progress, but also serves as a validation of ImmuVen’s T cell receptor technology platform,” says Cheryl Quinn, CEO of ImmuVen, Inc.
April 1, 2012
ImmuVen Receives $1.67 Million Phase II SBIR Award From NIH
- ImmuVen was awarded a Phase II SBIR totaling $1.67 million from the National Institute for Allergy and Infectious Disease for continuing development of therapeutics to neutralize Staphylococcal aureus toxins. For more information, click here.
ImmuVen develops novel drugs that can be used to treat infectious diseases and cancer. The company is located in Champaign, Illinois at the University of Illinois Research Park.
The company features a powerful, emerging life science technology, T cell receptors, a unique class of immune-targeting therapeutic and diagnostic agents. These agents have significant advantages over antibodies, which are already a $20 billion/year market against cancer, autoimmune, and infectious diseases.